Serina Therapeutics, Inc. Earnings Per Share Disclosure
| Year Ended December 31, | |||||||||||
| 2025 | 2024 | ||||||||||
| Net loss per common share attributable to common stockholders, basic and diluted | |||||||||||
| NUMERATOR | |||||||||||
| Net loss | $ | (19,215) | $ | (11,207) | |||||||
| Less: net loss attributable to noncontrolling interest | 33 | 66 | |||||||||
| Add: Cumulative undeclared Series A preferred stock dividends | (254) | — | |||||||||
| Net loss attributable to Serina common stockholders | $ | (19,436) | $ | (11,141) | |||||||
| DENOMINATOR | |||||||||||
| Weighted-average shares of common stock outstanding used to calculate basic net loss per common share | 10,190 | 7,359 | |||||||||
| Net loss per common share attributable to common stockholders, basic and diluted | $ | (1.91) | $ | (1.51) | |||||||
| December 31, | |||||||||||
| 2025 | 2024 | ||||||||||
| Stock options | 3,157 | 3,221 | |||||||||
| Warrants | 2,973 | 1,997 | |||||||||
| Series A convertible preferred stock | 1,022 | — | |||||||||
| Total anti-dilutive securities | 7,152 | 5,218 | |||||||||
Want the next Serina Therapeutics, Inc. earnings per share disclosure the moment it drops?
Set a Sentinel and we'll alert you the moment Serina Therapeutics, Inc.'s next filing hits EDGAR. No credit card, your email never gets sold.
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Mar 25, 2026 | Showing above |
| 2024 | Mar 24, 2025 | |
About Earnings Per Share Disclosures
The earnings per share disclosure breaks down the calculation from net income to both basic and diluted EPS, revealing the full impact of a company's capital structure on per-share economics. The reconciliation between basic and diluted share counts exposes how many stock options, RSUs, convertible securities, and warrants are potentially dilutive to existing shareholders.
Key signals: a widening gap between basic and diluted shares indicates growing dilution from equity compensation or convertible instruments. Anti-dilutive securities excluded from the diluted calculation deserve attention — they represent latent dilution that will materialize if the stock price rises. Watch for the effect of share buybacks on per-share metrics: EPS growth driven primarily by repurchases rather than income growth signals weakening fundamentals. Compare year-over-year changes in the diluted share count against equity compensation expense to assess whether management is effectively managing dilution.